<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00023621</url>
  </required_header>
  <id_info>
    <org_study_id>UCSF-U19-CA81888-BC</org_study_id>
    <secondary_id>CDR0000068817</secondary_id>
    <secondary_id>UCSF-H473-16531-02B</secondary_id>
    <secondary_id>NCI-P01-0190</secondary_id>
    <nct_id>NCT00023621</nct_id>
  </id_info>
  <brief_title>Celecoxib in Preventing Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome</brief_title>
  <official_title>A Phase II Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Celecoxib in Subjects With Basal Cell Nevus Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the&#xD;
      development of cancer. The use of celecoxib may be an effective way to prevent the&#xD;
      development of basal cell carcinoma.&#xD;
&#xD;
      PURPOSE: Randomized phase II trial to determine the effectiveness of celecoxib in preventing&#xD;
      basal cell carcinoma in patients who have basal cell nevus syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine whether celecoxib prevents the development of basal cell carcinoma in patients&#xD;
           with basal cell nevus syndrome.&#xD;
&#xD;
      OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients&#xD;
      are randomized to 1 of 2 arms.&#xD;
&#xD;
        -  Arm I: Patients receive oral celecoxib twice daily.&#xD;
&#xD;
        -  Arm II: Patients receive oral placebo twice daily. Treatment continues for 2 years in&#xD;
           the absence of unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 3 months for 3 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 60 patients (30 per arm) will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2001</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevention of the development of basal cell carcinoma</measure>
  </primary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Non-melanomatous Skin Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celecoxib</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed basal cell carcinoma (BCC)&#xD;
&#xD;
               -  At least 5 prior BCCs AND&#xD;
&#xD;
               -  At least 4 BCCs within the past year&#xD;
&#xD;
          -  Meets diagnostic criteria for basal cell nevus syndrome (BCNS)&#xD;
&#xD;
               -  Any 1 of the following:&#xD;
&#xD;
                    -  More than 2 BCCs or 1 before age 20&#xD;
&#xD;
                    -  Histologically confirmed odontogenic keratocysts of the jaw&#xD;
&#xD;
                    -  3 or more palmar and/or plantar pits&#xD;
&#xD;
                    -  Bilamellar calcification of the falx cerebri (if less than 20 years of age)&#xD;
&#xD;
                    -  Fused, bifid, or markedly splayed ribs&#xD;
&#xD;
                    -  First degree relative with BCNS&#xD;
&#xD;
                    -  PTC gene mutation in normal tissue OR&#xD;
&#xD;
               -  Any 2 of the following:&#xD;
&#xD;
                    -  Macrocephaly determined after adjustment for height&#xD;
&#xD;
                    -  Congenital malformations (e.g., cleft lip or palate, frontal bossing,&#xD;
                       &quot;coarse face&quot;, or moderate or severe hypertelorism)&#xD;
&#xD;
                    -  Skeletal abnormalities (e.g., Sprengel deformity, marked pectus deformity,&#xD;
                       or marked syndactyly of the digits)&#xD;
&#xD;
                    -  Radiological abnormalities (e.g., bridging of the sella turcica, vertebral&#xD;
                       anomalies, modeling defects of the hands and feet, or flame-shaped lucencies&#xD;
                       of the hands or feet)&#xD;
&#xD;
                    -  Ovarian fibroma&#xD;
&#xD;
                    -  Medulloblastoma&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 to 75&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC greater than 3,000/mm^3&#xD;
&#xD;
          -  Platelet count greater than 125,000/mm^3&#xD;
&#xD;
          -  Hemoglobin greater than 12.0 g/dL (women)&#xD;
&#xD;
          -  Hemoglobin greater than 13.0 g/dL (men)&#xD;
&#xD;
          -  No significant coagulation defect&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  ALT/AST no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  No chronic or acute hepatic disorder&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN&#xD;
&#xD;
          -  BUN normal&#xD;
&#xD;
          -  Electrolytes within normal&#xD;
&#xD;
          -  No chronic or acute renal disorder&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
        Gastrointestinal:&#xD;
&#xD;
          -  No active gastrointestinal disease&#xD;
&#xD;
          -  No inflammatory bowel disease&#xD;
&#xD;
          -  No chronic or acute pancreatic disorder&#xD;
&#xD;
          -  No history of gastrointestinal ulceration allowed except with permission of primary&#xD;
             care physician&#xD;
&#xD;
          -  No esophageal, gastric, pyloric channel, or duodenal ulceration within the past 30&#xD;
             days&#xD;
&#xD;
          -  Stool hematest normal&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No prior invasive malignancy within the past 5 years except nonmelanoma skin cancer,&#xD;
             stage I cervical cancer, stage 0 chronic lymphoblastic leukemia, or medulloblastoma&#xD;
&#xD;
          -  No hypersensitivity to COX-2 inhibitors, nonsteroidal anti-inflammatory drugs&#xD;
             (NSAIDs), salicylates, or sulfonamides&#xD;
&#xD;
          -  No other condition that would preclude study involvement&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 2 weeks since prior topical agents as chemoprevention&#xD;
&#xD;
          -  At least 1 year since other prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  At least 1 month since prior oral or IV corticosteroids&#xD;
&#xD;
          -  At least 6 months since prior inhaled corticosteroid use for longer than 4 weeks&#xD;
&#xD;
          -  At least 2 weeks since prior topical glucocorticoids&#xD;
&#xD;
          -  No concurrent topical glucocorticoids&#xD;
&#xD;
          -  Concurrent oral and IV corticosteroid use of less than 2 weeks within 6 months allowed&#xD;
&#xD;
          -  Concurrent inhaled corticosteroid use of less than 4 weeks within 6 months allowed&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 2 weeks since prior topical retinoids or alpha-hydroxy acids (e.g., glycolic&#xD;
             acid or lactic acid)&#xD;
&#xD;
          -  At least 2 weeks since prior topical medications&#xD;
&#xD;
          -  At least 30 days since prior investigational agents&#xD;
&#xD;
          -  At least 2 months since prior NSAIDs given more than 3 times/week&#xD;
&#xD;
          -  At least 2 months since prior aspirin dose of more than 100 mg/day given more than 3&#xD;
             times/week&#xD;
&#xD;
          -  At least 6 months since prior oral retinoids&#xD;
&#xD;
          -  No concurrent chronic NSAIDs (more than 3 times per week for at least 2 weeks)&#xD;
&#xD;
          -  No concurrent aspirin dose of more than 100 mg/day&#xD;
&#xD;
          -  No concurrent topical medications&#xD;
&#xD;
          -  No concurrent fluconazole&#xD;
&#xD;
          -  No concurrent lithium&#xD;
&#xD;
          -  No concurrent retinoids (including topical administration) or alpha-hydroxy acids&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ervin Epstein, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Tang JY, Wu A, Linos E, Parimi N, Lee W, Aszterbaum M, Asgari MM, Bickers DR, Epstein EH Jr. High prevalence of vitamin D deficiency in patients with basal cell nevus syndrome. Arch Dermatol. 2010 Oct;146(10):1105-10. doi: 10.1001/archdermatol.2010.247.</citation>
    <PMID>20956641</PMID>
  </results_reference>
  <verification_date>July 2007</verification_date>
  <study_first_submitted>September 13, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 25, 2013</last_update_submitted>
  <last_update_submitted_qc>June 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2013</last_update_posted>
  <keyword>basal cell carcinoma of the skin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Skin Neoplasms</mesh_term>
    <mesh_term>Basal Cell Nevus Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

